Inhibrx Biosciences, Inc.INBXNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank22
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-129.79M
↓ 52% vs avg
Percentile
P22
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-85.31M
Historical baseline
PeriodValueYoY Change
2025$-129.79M+33.2%
2024$-194.41M-0.6%
2023$-193.31M-67.7%
2022$-115.30M-43.5%
2021$-80.32M-67.5%
2020$-47.97M-49.5%
2019$-32.08M-38.9%
2018$-23.09M-23.1%
2017$-18.75M-3.6%
2016$-18.11M-